{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:27:35Z","timestamp":1772180855484,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1F1A1062978"],"award-info":[{"award-number":["NRF-2019R1F1A1062978"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The detection of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Ab) is essential for the diagnosis of MOG-Ab-associated disease (MOGAD). The clinical implications of different epitopes recognized by MOG-Ab are largely unknown. In this study, we established an in-house cell-based immunoassay for detecting MOG-Ab epitopes and examined the clinical characteristics of patients with MOG-Ab according to their epitopes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective review of patients with MOG-Ab-associated disease (MOGAD) in our single center registry, and collected serum samples from enrolled patients. Human MOG variants were generated to detect epitopes recognized by MOG-Ab. The differences in clinical characteristics according to the presence of reactivity to MOG Proline42 (P42) were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty five patients with MOGAD were enrolled. Optic neuritis was the most common presenting syndrome. The P42 position of MOG was a major epitope of MOG-Ab. The patients with a monophasic clinical course and childhood-onset patients were only observed in the group that showed reactivity to the P42 epitope.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed an in-house cell-based immunoassay to analyze the epitopes of MOG-Ab. The P42 position of MOG is the primary target of MOG-Ab in Korean patients with MOGAD. Further studies are needed to determine the predictive value of MOG-Ab and its epitopes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1200961","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T10:16:45Z","timestamp":1687774605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to their epitopes"],"prefix":"10.3389","volume":"14","author":[{"given":"Jin Myoung","family":"Seok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Hak","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonwook","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin Oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin Oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin Oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J Immunol"},{"key":"ref7","first-page":"201","article-title":"Cloning and cDNA sequence analysis of myelin\/Oligodendrocyte glycoprotein: a novel member of the immunoglobulin gene superfamily","volume":"144","author":"Gardinier","year":"1993","journal-title":"Schweiz Arch Neurol Psychiatr (1985)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4049\/jimmunol.181.2.1255","article-title":"Demyelinating myelin Oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents","volume":"181","author":"Breithaupt","year":"2008","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.23838\/pfm.2021.00198","article-title":"Autoantibodies in central nervous system and neuromuscular autoimmune disorders: a narrative review","volume":"6","author":"Jeon","year":"2022","journal-title":"Precis Future Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin Oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO Spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The Spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin Oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin Oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin Oligodendrocyte glycoprotein in Neuromyelitis Optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with Neuromyelitis Optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult Scler"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103253","DOI":"10.1016\/j.msard.2021.103253","article-title":"High titers of myelin Oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics","volume":"56","author":"Lui","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin Oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1212\/CON.0000000000001127","article-title":"Myelin Oligodendrocyte glycoprotein-associated disorders","volume":"28","author":"Longbrake","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jnnp-2019-322115","article-title":"Myelin Oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese Paediatric-onset cohort","volume":"91","author":"Sun","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acn3.51378","article-title":"No strong HLA association with MOG antibody disease in the UK population","volume":"8","author":"Grant-Peters","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974-016-0678-4","article-title":"Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system","volume":"13","author":"Sinmaz","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e200035","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/13524585221093789","article-title":"Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria","volume":"28","author":"Fadda","year":"2022","journal-title":"Mult Scler"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with Neuromyelitis Optica Spectrum disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1212\/NXI.0000000000000625","article-title":"Identification of circulating MOG-specific B cells in patients with MOG antibodies","volume":"6","author":"Winklmeier","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1200961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T10:16:51Z","timestamp":1687774611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1200961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":29,"alternative-id":["10.3389\/fneur.2023.1200961"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1200961","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"1200961"}}